Novelty and Impact: The nonseminoma subtype of testicular germ cell cancer is characterized by totipotency of the cancer stem cell which may differentiate into all embryonal tissue lineages.
Introduction
Malignant germ cell tumors of the adult testis, referred to as type II TGCTs of testicular germ cell cancer (TGCC), are the most frequent cancer in young Caucasian males 1 . TGCC are thought to be initiated during early embryogenesis affecting an embryonic germ cell, and become clinically manifest during young adulthood with an annual frequency of approximately 5-12 per 100,000 men in the western world and may require "aggressive" medical treatment.
These cancers are clinically and histologically classified into two variants, being seminoma (SE) and nonseminoma (NS). Both arise from a common cancer stem cell, currently referred to as Germ Cell Neoplasia In Situ (GCNIS) 2, 3 , which resembles totipotent primordial germ cells (PGC) / gonocytes. Patients with proven GCNIS have a 70% chance of progression to TGCC (both SE and NS) within 7 years. SE consists of a homogeneous population of cells with similarity to GCNIS and PGC/gonocytes. About 50% of the TGCC patients present with a NS, that can be composed of different histological elements, embryonal carcinoma (EC), teratoma (TE), yolk sac tumor (YST), and choriocarcinoma (ChC), either pure or mixed. The EC is the pluripotent stem cell component of NS, which can mimic normal early embryogenesis including the formation of so called embryonal bodies (EB), and thereby give rise to all differentiated components [3] [4] [5] .
Although all TGCC, including mature TE, are in principle capable to metastasize, about 80-85% of the SE patients and 55-60% of the NS patients present with localized (stage I) disease. Patients with metastatic TGCC are generally cured by standard treatment regimens involving platinum compounds and additional surgery for residual teratoma, while only few patients show resistance to treatment 6 . So far, detailed studies into the molecular profile of TGCCs and their progression stages were focused on specific genes, like KIT 7 and TP53 [8] [9] [10] , and on the chromosomal constitution. Analyses have revealed many changes in the (relative) number of individual chromosomes in the different tumor components 5, [11] [12] [13] [14] [15] [16] . Gain of the short arm of chromosome 12 is a hall mark of (invasive) TGCCs 17 , but as yet no causative gene (s) have been identified. Information on driver mutations underlying the development of these cancers using exome sequencing is scarce 11-14, 18, 19 .
In order to unravel the molecular heterogeneity of TGCC, we extensively investigated four rare cases of primary therapy-resistant NS and performed WGS on the primary cancer and targeted sequencing analyses on 42 enriched histological components, precursor cell populations, and metastatic lesions after treatment ( Fig. 1A/B ). Focus was on the early events of tumor formation, the molecular heterogeneity within the primary lesion and the retention of molecular markers in the metastatic recurrences. Additionally, data from RNA expression (RNAseq) and copy number alterations (CNA) from high throughput DNA methylation profiling and DEPArray TM /LowPass WGS were interrogated to decipher the evolution of the disease. 
Methods

Further
Omics analyses of patient samples
Purified tumor components ( Supplementary Table S1 ), as defined by an experienced pathologist (JWO), were isolated from frozen tissue slices after staining for alkaline phosphatase enzyme reactivity (dAP) 20 , using PALM micro-dissection (Zeiss). Tumor and paired normal DNA samples were whole genome sequenced (40 times coverage) and analyzed at Complete Genomics Inc. (CG) (Mountain View, CA, USA) using NCBI build 36.3 as human reference genome and pipeline software version 2.0.2.22 21 . Lists of putative SNV were established from the WGS data as described in the Supplementary Methods. SNV were verified using mutation-specific Q-PCR, targeted sequencing ( Supplementary Tables S2&S3), and RNA-seq. Structural variants were evaluated for gene fusions with iFuse 22 . Characterization of the mutational signature was done by comparison of the trinucleotide context of each SNV to the established COSMIC signatures using the MutationalPatterns R package (v1.0) 23 .
Targeted sequencing was performed by semiconductor sequencing with the Ion Torrent Personal Genome Machine with supplier's materials and protocols (ThermoFisher Scientific) as previously described 24 . Amplicons were designed to cover tumor-specific SNV, structural variants and heterozygote positions ( Supplementary Table S3 ). Median sequencing depth was at least 250 reads. Allele frequencies were established for the heterozygous positions in the matched normal samples present on the amplicons. Details for calling of SNP, SNV and structural variants in the targeted sequencing experiments are provided in the Supplementary Methods. Evolutionary trees of different samples of a specific tumor were drawn based on the LAF and SNV profiles and supported by the TargetClone tool. TargetClone was designed to reconstruct evolutionary trees for multiple samples of a cancer using allele frequencies and SNV (Nieboer MM, Dorssers LCJ, Straver R, Looijenga LHJ, de Ridder J, manuscript in preparation and Supplementary Methods).
RNA samples of T6107 and T3209 were rRNA-reduced and Ion Proton sequenced (90 bases, 50 million mapped reads) using the supplier's protocols and reagents (ThermoFisher Scientific). Generation of methylation profiles of primary tumor DNA was performed as previously described 25 
Results
Primary nonseminoma characteristics
To address tumor heterogeneity and progression, WGS data from four primary chemonaïve NS were exploited. Comparison of the primary tumors with the matched normal provided a set of 1239 somatic putative DNA variants (SNV) for these cases (Fig. 1B) . RNAseq, mutation-specific PCR and targeted sequencing experiments validated 150 out 158 SNV and nine out of 15 structural variants ( Fig 1B, Supplementary Tables S4 and S5 ). The identified mutations causing protein changes have been listed in Table 1 . Only four SNV resulted in protein truncation and another 13 were predicted to be damaging ( Supplementary Table S6 ). In addition, detailed information regarding structural variants, lesser allele frequencies (LAF) and chromosome copy number alterations (CNA) were obtained from the WGS and methylation profiling (details in Supplementary Figs. S1 & S2). The trinucleotide profile of single base SNV identified by WGS of the four TGCC was determined and compared to the established set of COSMIC mutational signatures 28 . In all cases (Fig. 1C ), signature 3 contributed significantly or was the predominant signature. Analysis of the pooled SNV (from whole exome sequencing) of independent cases of NS (N=18) and SE (N=18) 14 , also revealed this signature to be the most prominent ( Fig. 1C and further details in Supplementary Fig. S3 ). This signature 3 is strongly associated with mutations in BRCA1 or BRCA2, genomic deletion and insertion events smaller than 100kb, and a deficiency in homologous recombination repair in breast cancer 29 . In the absence of substantial numbers of indels and genomic deletion and insertion events in our WGS data, additional support for recombination repair deficiency is lacking. Furthermore, somatic mutations in BRCA1 or BRCA2 were not observed in the four included TGCC, although case T1382 carried a predicted, non-pathogenic BRCA1 missense variant ( Supplementary   Table S6 ), nor in the cases of the Taylor-Weiner study 14 . In addition, promoter hypomethylation and RNAseq reads for both genes did not support loss of BRCA function ( Supplementary Fig.   S4 ).
Molecular heterogeneity and evolution
For the study of the molecular heterogeneity within these histologically complex primary TGCC (containing EC, EB, TE and YST components, Fig 1A) , matched metastases and precursor lesions, DNA was prepared from various micro-and macro-dissected components (N=42, Fig. 1A Supplementary Table S1 ). The histological identity was determined by an experienced pathologist, and using direct alkaline phosphatase (dAP)-staining for EC, EB and GCNIS in frozen tissue (examples in Supplementary Fig. S5 ) 20 . To evaluate the allelic imbalances and the presence of SNV in these enriched specimens, amplicons were designed across the genome containing a tumor-specific SNV and additional heterozygous SNPs (Supplementary Fig. S1 and Supplementary Table S3 ). For the primary tumor DNA samples, an excellent agreement between the LAF profiles of the WGS and targeted analyses was observed ( Supplementary Fig. S6 ). Analyses of the enriched samples were focused on the LAF of germ line heterozygote SNPs, the read frequencies of the SNV and the presence of specific breakpoints. Furthermore, evolutionary trees based on the LAF and the presence of SNV, and supported by TargetClone, were generated for each case. Results of these analyses will be discussed per case below.
T6107: The majority of the allelic imbalances and SNV found in the primary cancer were present and more easily detected in the enriched malignant histologies due to their increased purity and the removal of contaminating normal cells (example in Fig. 1D ). Loss of heterozygosity (LOH) was clearly resolved for chromosome (arm) 4q, 10, 11, 13 and 16q for the purified EC component. The false color plot showed extensive overlap in regional allelic imbalances and SNV amongst the enriched histological components of T6107 and compared to the primary NS ( Fig. 2A/B and Supplementary Fig. S7A ). LOH on the chromosomes mentioned above was preserved in all histological elements (homogeneously red colored blocks indicating LAF<0.1, Fig. 2A ). Sample EC21 displayed additional LOH resulting from copy losses of chromosomes arms 9q and 22q. In the GCNIS preparations (CIS30&FCIS31, Fig. 2A ), very little overlap in LAF patterns with the primary NS was observed and the majority of SNV were completely absent (Fig. 2B ). The yolk sack tumor metastasis in the lung (YSTmeta) showed minor overlap with the primary NS and its histological components with regard to LAF pattern and presence of SNV. The shared LOH of chromosome arm 22q between EC21 and this metastasis represented independent events based on the different parental alleles retained ( Supplementary Fig. S8 ). Presence of chromosome arm 12p gain ( Supplementary Fig. S9 ), and two SNV ( Fig. 2B ) in this metastasis demonstrated a shared origin with the primary NS. The copy number profiles of this lung metastasis and a prior retroperitoneal lymph node metastasis with the histology of mature TE displayed many novel alterations, including amplification of the MDM2 region (details in Supplementary Fig. S9 ). IHC and FISH analysis confirmed the amplification of MDM2 and targeted sequencing did not reveal TP53 mutation in the lung metastasis (not shown). An evolutionary tree for this case (Fig. 3 ) was based on the general profiles of the LAF and SNV ( Fig Furthermore, the early ECx1 precursor was the founder of the late appearing lung metastasis (YSTmeta) and likely of the mature TE in the lymph node metastasis ( Supplementary Fig. S9 ), which both lacked many of genomic marks of the primary tumor. Supplementary Fig, S10 ). The evolutionary tree of this case (Fig. 3) required the insertion of an unidentified precursor (GCNISx) as the progressed state GCNIS (BCIS28 and FCIS27) showed loss of alleles on chromosome arms 11q and 22qter, which were retained by the primary tumor ( Supplementary Fig. S8 ). These data strongly suggest that the abundant basal and floating GCNIS adjacent to the tumor mass represent a precursor clone that did not progress to a full malignant state and was not the founder of the primary NS.
T1382: The enriched samples were all derived from old FFPE tissue blocks and showed more amplicon drop out and noisy LAF data ( Supplementary Fig. S7D ). In spite of this limitation, the enriched TE and EC histologies showed good overlap for LAF, SNV, and breakpoints with the primary NS. A set of SNV, breakpoints and regions of imbalance appeared preserved in some of the metastases, while novel alterations were also observed (details in Supplementary   Fig. S7D ). The evolutionary tree based primarily on the SNV required the insertion of a nonidentified EC precursor to explain the differences between the primary TGCC components and the metastases (Fig. 3 ).
Discussion
Our studies on multiple samples of four cases of therapy-resistant TGCC provided insight in the complexity of tumorigenesis (Fig. 4 ). TGCC carried low numbers of SNV (~0.1 per Mb, Fig. 1B) , somewhat lower than reported previously [12] [13] [14] and comparable to some of the pediatric cancers and spermatocytic tumors 28, 30 . The total number of SNV with a predicted impact on the encoded protein (3 -16, Table 1 ) was similar to other reports [11] [12] [13] . Overlap of mutated genes belonging to specific pathways was not observed within this small series of TGCC cases and was limited with genes reported for primary untreated TGCC (ASAP1, BRCA1, CCKBR, CROCC, CSE1L, KAT6A, KEAP1, MTOR, MYOM3 and TAF7) 11-14, 31, 32 .
NS exhibited clonal heterogeneity which did not correlate with the histological subtypes ( Fig. 3 ). This was expected because of EC being the stem cell component of all differentiated NS elements in the primary TGCC and different EC precursors providing independent lineages of differentiated cells 5, 33 . A typical example is provided by the T3209 EB23 which resembles an early developing embryo derived from a single EC with a different genomic make-up ( Supplementary Fig. S7B ). Extensive intratumor heterogeneity was also reported for non-smallcell lung cancer 34 . Our analyses also showed that metastatic clones can be derived from very early cancer stem cells that are underrepresented or even absent in the primary lesion, and not detected with the current approaches ( Fig. 4) . Early disseminated cells have been shown to seed metastases in models of breast, pancreatic, bladder and melanoma [35] [36] [37] [38] , but appeared less predominant in breast cancer patients 39 .
The comparison of the primary tumor and the highly enriched tumor histologies revealed that the read frequencies of SNV on the autosomes (even in regions with LOH) hardly ever exceeded the 50% level (examples in Supplementary Figs . S1, S6 and S7), indicating that always a wild type copy of the particular gene was retained within the cancer genome. Similarly, the relative read frequencies of the SNV present in the GCNIS cells were low (< 0.34 for case T618, Fig. 2D ) and therefore likely limited to a single allele copy. These results indicate that whole genome duplication preceded the gain of most somatic mutations 34, 39 .The single SNV identified in the GCNIS of T6107 was present in high relative read frequencies (up to 50%), suggesting that this mutational event preceded genome duplication (Fig. 2B) . Alternatively, this specific variant may represent mosaicism resulting from somatic mutation in early embryonic cells 40, 41 . Genome doubling may also underlie development of esophageal cancer following early TP53 inactivation 42 . The status of the overrepresentation of the 12p region in the purified cancer stem cells GCNIS remains uncertain, but the observed balanced allele frequencies are in line with absence of 12p gain ( Fig. 2A&2C & Supplementary Fig. S8 ). Furthermore, LowPass WGS on DEPArray purified T618 GCNIS, revealed no gain of 12p and absence of the majority of CNA present in the primary TGCC ( Supplementary Fig. S10 ). These results are in agreement with the notion that accumulation of chr12p copies coincides with acquirement of invasive behavior ( Fig. 4) 17, 43, 44 .
Our data and the lack of recurrent driver mutations support the hypothesis that whole genome duplication is the primary event in TGCC development (Fig. 4) , to be followed by overall net chromosome copy losses 4, 45 . Final proof for early whole genome duplication may be obtained using digital NGS based on Barcode-In-Genome technology on many individual GCNIS to determine actual chromosome copy numbers 46 . Subsequently, gain of 12p copies (which may be dynamic in subclones, details Supplementary Fig. S7 ), gain of limited numbers of somatic mutations, and additional CNA will trigger the development of the primary TGCC (Fig.   4 ). In order to prevent accumulation of genomic mutations in germ cells, active surveillance and removal of PGCs with an aberrant genome is very efficient 47, 48 . All PGCs are completely demethylated and considered to be prone to aneuploidy 49 , but incidence of TGCC is low in the male population. Removal of aberrant GCNIS may require functional TP53 which could be interrupted by gene mutation or by defined miRNAs 50, 51 . In agreement with their extreme sensitivity to cisplatin-based therapies, TP53 mutations are extremely rare in primary TGCC indicating no selective pressure 10, 14, 51 . The presence of an amplified MDM2 locus in two metastases of case T6107 ( Supplementary Fig. S9 ) may have provided an alternative route for inactivation of TP53 and therapy resistance 10, 31, 52 . The BRCA-like base substitution signature of this cancer hints at inefficient homologous recombination repair 53 . However, there is currently no evidence for the direct involvement of the BRCA genes (absent gene mutation or promoter hypermethylation, and no rearrangement signature 29 , and no association of TGCC with familiar BRCA1/2 mutations). It is tempting to speculate that other components of this homologous recombination repair pathway may be affected and responsible for the specific base substitution signature in the absence of direct involvement of BRCA genes 29, 53 . Alternatively, BRCA-related repair functions may be low or turned off intrinsically in the embryonic PGC/gonocytes 54 
Conclusions
The observed heterogeneity in the primary tumor, metastases and precursor lesions of nonseminoma ( Fig. 4 ) may impact on clinical decisions and treatment strategies. The occurrence of metastatic tumors with little molecular overlap with the primary lesion indicates that treatment should be targeted at the properties of the individual metastasis. The identification of abundant cancer stem cells GCNIS which did not contribute to the development of the TGCC further complicates the clinical advice to patients with GCNIS only disease 56 . In view of its tendency to progress in 70% of the patients within 7 years, novel predictive markers for the GCNIS progression are needed. The BRCA-like mutational signature in TGCC suggestive for impaired homologous recombination repair, may suggest the combined use of PARP inhibitors and platinum-based therapy 57 for primary TGCC and non-teratoma recurrences. Further studies into NS and SE cases, with GCNIS adjacent to the primary tumor and different histologies or localization, are needed to identify reliable markers for GCNIS progression, to unravel the critical steps for malignancy and therapy resistance, and to decipher the BRCA-like mutational signature of TGCC. Supplementary Table S4 ). Structural variants (SV) were confirmed for selected cases using targeted sequencing. Mutations occurring near exon boundaries were evaluated for potential effect on splicing using Alamut Software. Details are provided in Supplementary Tables S4-S6. The bottom panel shows the number of purified histological components isolated and analyzed for these cases. PBL = peripheral blood leukocytes; NAP = nonmalignant adjacent parenchyma.
C. The mutational profiles of these four NS were compared to the 30 COSMIC signatures described. The mutational signatures contributing significantly (>5%) are presented. In addition, the SNV of NS and SE cases from the Taylor-Weiner study (*) 14 were pooled for tumor subtype and similarly analyzed. The number of SNV used for the analysis is indicated below each bar. Table 1 ).
In addition, the presence of tumor-specific structural variants is indicated (marked with green arrow heads, missing data in white, absent in light gray, low numbers of reads in gray, many reads in black). A red arrow marks a SNV present in all samples (except PBL) from case T6107 (chr19:56131557), residing in a 2kb region between two Zn-finger genes. The number at the bottom indicates the months after surgery of the primary tumor that the metastasis was removed. E: Color keys for the different categories. Sample information and targeted sequence data are provided in Supplementary Table S1 and Table S8 . Fig. 2 and Supplementary Fig. S7 ) and supported by TargetClone Table 1 . Somatic mutation derived protein variants. Somatic mutation of genes leading to (putative) protein changes per case. The mutation type, RNA nucleotide (NT) and amino acid (AA) changes are indicated. The last three columns provide the occurrence of the DNA mutation (samples with mutation / samples successfully sequenced) in the different enriched sample types (GCNIS, histologies of the primary tumor, and metastases). n.d. = not detected, indicating that the sequencing of the specific target was not successful.
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